J.P. Morgan Resumes Coverage on Pfizer (PFE) with an Overweight
Tweet Send to a FriendGet Alerts PFE Hot Sheet
Price: $28.78 +0.28%
Rating Summary:
13 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
13 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade PFE Now!
J.P. Morgan resumes coverage on Pfizer (NYSE: PFE) with an Overweight rating. Price target $21.
To see more analyst ratings on PFE Click Here.
Pfizer Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide.
To see more analyst ratings on PFE Click Here.
Pfizer Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide.
You May Also Be Interested In
- Pfizer (PFE) Discontinues Phase 3 Study of Inotuzumab Ozogamicin
- BMO Capital Starts Dr Pepper Snapple (DPS) at Market Perform
- Standpoint Research Starts Vera Bradley (VRA) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
JPMorgan
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
